Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.
You may also be interested in...
Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination
Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.
Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination
Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.
Anticipating Pixantrone Approval, Cell Therapeutics Adopts A "Poison Pill" Plan
The shareholder rights plan includes a provision that is intended to forestall a hostile takeover bid.